Sage Therapeutics Inc (SAGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has a cash flow conversion efficiency ratio of -0.159x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.69 Million) by net assets ($368.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sage Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Sage Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sage Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sage Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sage Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Sage Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yantai Longyuan Power Tech
SHE:300105
|
0.094x |
|
Chularat Hospital Public Company Limited
BK:CHG
|
0.032x |
|
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
|
N/A |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
-0.095x |
|
VRL Logistics Limited
NSE:VRLLOG
|
0.293x |
|
Shenzhen Silver Basis Technology Co Ltd
SHE:002786
|
0.318x |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
0.028x |
|
Brightspire Capital Inc
NYSE:BRSP
|
0.012x |
Annual Cash Flow Conversion Efficiency for Sage Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sage Therapeutics Inc from 2012 to 2024. View SAGE stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $465.09 Million | $-267.19 Million | -0.575x | +15.03% |
| 2023-12-31 | $799.53 Million | $-540.59 Million | -0.676x | -84.10% |
| 2022-12-31 | $1.25 Billion | $-460.04 Million | -0.367x | -67.91% |
| 2021-12-31 | $1.73 Billion | $-378.18 Million | -0.219x | -168.23% |
| 2020-12-31 | $2.07 Billion | $664.28 Million | 0.321x | +157.27% |
| 2019-12-31 | $944.65 Million | $-528.71 Million | -0.560x | -85.29% |
| 2018-12-31 | $862.97 Million | $-260.67 Million | -0.302x | +34.50% |
| 2017-12-31 | $475.48 Million | $-219.28 Million | -0.461x | -43.20% |
| 2016-12-31 | $368.52 Million | $-118.68 Million | -0.322x | +20.86% |
| 2015-12-31 | $173.69 Million | $-70.68 Million | -0.407x | -83.41% |
| 2014-12-31 | $121.89 Million | $-27.04 Million | -0.222x | -139.94% |
| 2013-12-31 | $-31.54 Million | $-17.52 Million | 0.555x | -16.65% |
| 2012-12-31 | $-13.39 Million | $-8.93 Million | 0.666x | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more